protein

PAFAHB Protein, Human (His)

HY-P71185

10 μg;50 μg

155;430 USD

PAFAHB Protein, Human (His)

proteins

E. coli

10 μg;50 μg

155;430 USD

PAFAHB Proteinas, incorporating Alpha-2 adrenergic receptors, facilitates catecholamine-induced adenylate cyclase inhibition through G proteins. Notably, oxymetazoline ranks as the most potent agonist, followed by clonidine and antagonists with yohimbine exhibiting the highest inhibitory activity. This insight into agonist and antagonist effectiveness sheds light on the pharmacological modulation of Alpha-2 adrenergic receptors by ADRA2A-VLPs. PAFAHB Protein, Human (His) is the recombinant human-derived PAFAHB protein, expressed by E. coli , with C-6*His labeled tag. The total length of PAFAHB Protein, Human (His) is 228 a.a., with molecular weight of ~31.0 kDa.

Human

ADRA2A-VLPs, as a construct incorporating Alpha-2 adrenergic receptors, facilitate the catecholamine-induced inhibition of adenylate cyclase via G proteins. The receptor exhibits distinct agonist and antagonist pharmacological profiles. Among agonists, oxymetazoline demonstrates the highest potency, followed by clonidine, epinephrine, norepinephrine, phenylephrine, dopamine, p-synephrine, p-tyramine, serotonin, and p-octopamine. Conversely, antagonists show varying degrees of inhibitory activity, with yohimbine ranking as the most potent, followed by phentolamine, mianserine, chlorpromazine, spiperone, prazosin, propranolol, alprenolol, and pindolol. This delineation of agonist and antagonist effectiveness provides valuable insights into the pharmacological modulation of Alpha-2 adrenergic receptors mediated by ADRA2A-VLPs.

Platelet-Activating Factor Acetylhydrolase IB Subunit Beta; PAF Acetylhydrolase 30 kDa Subunit; PAF-AH 30 kDa Subunit; PAF-AH Subunit Beta; PAFAH Subunit Beta; PAFAH1B2; PAFAHB

Greater than 95% as determined by reducing SDS-PAGE.

Supplied as a 0.2 μm filtered solution of 20 mM Tris-HCl, 150 mM NaCl, pH 8.0.

Shipping with dry ice.